Patents Assigned to The Trustee of the University of Pennsylvania
  • Methods and compositions for cells expressing a chimeric intracellular signaling molecule
    Patent number: 11890301
    Abstract: The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an chimeric antigen receptor and bispecific antibodies in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. Certain aspects include modified T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: February 6, 2024
    Assignees: The Trustees of the University of Pennsylvania, Wayne State University
    Inventors: Carl H. June, Michael Milone, Yangbing Zhao, Lawrence G. Lum, Archana Thakur
  • Thioamide-modified peptides and uses thereof
    Patent number: 11891425
    Abstract: The invention includes a thioamide-modified peptide, wherein the thioamide modification increases the in vivo half-life of the peptide. The invention further includes methods of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering to the subject a thioamide-modified peptide of the invention.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: February 6, 2024
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: E. James Petersson, Alan Saghatelian
  • AAV9-mediated gene therapy for treating mucopolysaccharidosis type I
    Patent number: 11890329
    Abstract: A co-therapeutic regimen comprising AAV9-mediated intrathecal/intracisternal and/or systemic delivery of an expression cassette containing a hIDUA gene and two or more immunosuppressants is provided herein. Also provided are methods useful for treating hIDUA deficiency (MPSI) and the symptoms associated with Hurler, Hurler-Scheie and Scheie syndromes.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: February 6, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Christian Hinderer, James M. Wilson
  • Methods, systems, and computer readable media for extended reality user interface
    Patent number: 11893696
    Abstract: Methods, systems, and computer readable media for providing an extended reality (XR) user interface. A method for providing an XR user interface occurs at a user device executing an XR application.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: February 6, 2024
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Stephen H. Lane, Matthew Anthony Boyd-Surka, Yaoyi Bai, Aline Sarah Normoyle
  • Extreme polyvalency induces potent cross-clade cellular and humoral responses in rabbits and non-human primates
    Patent number: 11883484
    Abstract: The present invention relates to compositions comprising two or more DNA plasmids encoding consensus and transmitted founder HIV envelope glycoproteins which expressed and induce a potent immune response.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: January 30, 2024
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology
    Inventors: David Weiner, Megan Wise
  • Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
    Patent number: 11883470
    Abstract: A synthetic or recombinant human lecithin cholesterol acyltransferase (LCAT) variant is provided which comprises an LCAT enzyme having a substitution at position 114 based on the residue numbering of wild-type (WT) human LCAT [SEQ ID NO:1], wherein said variant is characterized by one or more of: (i) an esterification rate higher than the esterification rate of WT human LCAT; and/or (ii) an association with higher density lipoprotein levels as compared to subjects having WT LCAT. Also provided are vectors encoding the variant, compositions containing same, and methods of using the variant proteins and vectors for treatment of a variety of disorders associated with defective wt LCAT.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: January 30, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daniel Rader, Devin Christopher, Anna P. Tretiakova
  • Compstatin analogs with increased solubility and improved pharmacokinetic properties
    Patent number: 11884747
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus and/or C-terminus contains an added component that improves (1) the peptide's solubility at physiological pH; (2) the peptide's plasma half-life; (3) the peptide's intraocular retention; and/or (4) the peptide's binding affinity to C3 or its fragments as compared to an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 30, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: John D. Lambris
  • Compositions and methods of phospholipase A2 receptor chimeric autoantibody receptor T cells
    Patent number: 11884716
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: January 30, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Saar Gill, Jonathan Hogan, Aimee S. Payne, Baomei Wang
  • NOVEL COMPOSITIONS WITH TISSUE-SPECIFIC TARGETING MOTIFS AND COMPOSITIONS CONTAINING SAME
    Publication number: 20240024507
    Abstract: Provided herein are compositions including targeting peptides linked thereto or inserted in a targeting protein of a recombinant vector having at least one exogenous peptide comprising an amino acid sequence of N-x-(T/I/V/A)-(K/R) (SEQ ID NO: 47). Compositions providing such conjugates, targeting peptides, or recombinant vectors having a mutant capsid or envelope protein are provided as are uses thereof.
    Type: Application
    Filed: December 1, 2021
    Publication date: January 25, 2024
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Joshua Joyner Sims, Yuan Yuan
  • MODIFIED MRNA VACCINES ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEINS AND USES THEREOF
    Publication number: 20240024463
    Abstract: The present invention provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified mRNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.
    Type: Application
    Filed: September 19, 2023
    Publication date: January 25, 2024
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Harvey FRIEDMAN, Drew WEISSMAN, Sita AWASTHI, Gary Cohen
  • Systems and methods for mesh delivery and prevention of port-site hernia
    Patent number: 11877743
    Abstract: The presently disclosed subject matter provides systems and methods for performing minimally invasive surgery. A laparoscopic device for performing minimally invasive surgery can include a mesh configured to be affixed to a fascial tissue to reinforce the fascial tissue. The mesh can be attached to the laparoscopic device before the mesh reaches the fascial tissue. The laparoscopic device can also include a telescoping arm configured to deliver the mesh to the fascial tissue. The telescoping arm can be further configured to position the mesh at the fascial tissue by releasing the mesh from the laparoscopic device.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: January 23, 2024
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: John Fischer, Rex Peters
  • Gene therapy for ocular disorders
    Patent number: 11879133
    Abstract: Compositions and methods are provided for treating ocular neuropathy in a subject. In one aspect, a recombinant adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding NRF2. In another aspect, a recombinant adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding SIRT1. In desired embodiments, the subject is human, cat, dog, sheep, or non-human primate.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: January 23, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jean Bennett, Junwei Sun, Kenneth Shindler, Devin McDougald, Ahmara Gibbons Ross
  • RNA VACCINES ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEINS AND USES THEREOF
    Publication number: 20240016922
    Abstract: The present disclosure provides compositions for the prevention and treatment of genital herpes, comprising nucleoside-modified RNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.
    Type: Application
    Filed: August 3, 2023
    Publication date: January 18, 2024
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Harvey FRIEDMAN, Sita AWASTHI, Gary Cohen, Drew WEISSMAN
  • GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II
    Publication number: 20240016903
    Abstract: A co-therapeutic regimen comprising AAV9-mediated intrathecal/intracisternal and/or systemic delivery of an expression cassette containing a hIDS gene and two or more immunosuppressants is provided herein. Also provided are methods and kits containing these vectors and compositions useful for treating Hunter syndrome and the symptoms associated with Hunter syndrome.
    Type: Application
    Filed: August 17, 2023
    Publication date: January 18, 2024
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Christian Hinderer, James M. Wilson
  • Transcriptome in vivo analysis (TIVA) and transcriptome in situ analysis (TISA)
    Patent number: 11873312
    Abstract: Compositions and methods of capturing one or more nucleic acid molecules of a cell or subcellular compartment are described. In certain aspects, the compositions comprise a caged molecule comprising one or more photolinkers and an antisense oligonucleotide, which when uncaged hybridizes to a target nucleic acid molecule.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: January 16, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James Eberwine, Ivan J. Dmochowski, Sean B. Yeldell, Julianne C. Griepenburg, Teresa L. Rapp, Jennifer M. Singh, Jai-Yoon Sul, Jaehee Lee
  • Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain
    Patent number: 11872249
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: January 16, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Walter Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Patricia Pinto Guimaraes, Saar Gill, Marco Ruella, Regina M. Young
  • COMPOSITIONS AND METHODS FOR GENOMIC DNA AND GENE EXPRESSION ANALYSIS IN SINGLE CELLS
    Publication number: 20240011025
    Abstract: Provided herein are compositions and methods to assess the genomic landscape of fixed cells using light activated oligonucleotides that can be directed to the nucleus, mitochondria, or cytoplasm of fixed cells and that, upon activation, can be extended for in situ copying of nuclear single-stranded DNA (i.e., open chromatin), open mitochondrial DNA, and/or cytoplasmic RNA into barcoded complementary DNA. These methods also provide for gene specific 3D chromatin structural niche analysis.
    Type: Application
    Filed: June 15, 2023
    Publication date: January 11, 2024
    Applicants: Agilent Technologies, Inc., The Trustees of the University of Pennsylvania
    Inventors: James EBERWINE, Jae-Hee LEE, Jifen LI, Stephen FISHER, Youtao LU, Junhyong KIM, Jai-Yoon SUL, Jinchun WANG, Mimi HEALY
  • GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS IIIB
    Publication number: 20240009327
    Abstract: Provided herein is a recombinant AAV (rAAV) comprising an AAV capsid and a vector genome packaged therein, wherein the vector genome comprises an AAV 5? inverted terminal repeat (ITR), an engineered nucleic acid sequence encoding a functional human N-acetyl-alpha-glucosaminidase (hNAGLU), a regulatory sequence which direct expression of hNAGLU in a target cell, and an AAV 3? ITR. Also provided is a pharmaceutical composition comprising a rAAV as described herein in a formulation buffer, and a method of treating a human subject diagnosed with MPS IIIB.
    Type: Application
    Filed: July 10, 2023
    Publication date: January 11, 2024
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Christian Hinderer, Juliette Hordeaux
  • VIRAL VECTORS ENCODING CANINE INSULIN FOR TREATMENT OF METABOLIC DISEASES IN DOGS
    Publication number: 20240010699
    Abstract: Compositions and methods for treating diabetes in a canine are provided. A viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding a canine insulin polypeptide.
    Type: Application
    Filed: November 4, 2021
    Publication date: January 11, 2024
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Christian Hinderer, Makoto Horiuchi
  • Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
    Patent number: 11865167
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: January 9, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania, University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Jennifer Brogdon, Laura Alexandra Johnson, Carl H. June, Andreas Loew, Marcela Maus, John Scholler, Hideho Okada